Abstract |
This article presents considerations currently under discussion about the probability of HP participation in the ulcer causation as well as information about Rabeprazole efficiency for anti-helicobacter therapy of non-complicated duodenal ulcer (as a result of 7-day anti-helicobacter therapy, the healing of duodenal bulbs was recorded in 82.6% of cases; HP eradication was recorded in 86.9% of cases 4 weeks after the termination of the treatment) based on the analysis of scientific literature data and personal experience. Considerations related to the conduction of a possible study in the field of ulcer therapy that is not associated with Helicobacter pylori are presented.
|
Authors | Iu B Vasil'ev |
Journal | Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology
(Eksp Klin Gastroenterol)
Issue 3
Pg. 14-8, 102
( 2004)
ISSN: 1682-8658 [Print] Russia (Federation) |
Vernacular Title | Vybor variantov medikamentoznoĭ terapiii neoslozhnennoĭ iazvennoĭ bolezni dvenadtsatiperstnoĭ kishki (po rezul'tatam izucheniia éffektivnosti rabeprazola). |
PMID | 15560394
(Publication Type: Journal Article, Review)
|
Chemical References |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Anti-Ulcer Agents
- Benzimidazoles
- Rabeprazole
- Omeprazole
|
Topics |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Anti-Ulcer Agents
(therapeutic use)
- Benzimidazoles
(therapeutic use)
- Duodenal Ulcer
(drug therapy, microbiology)
- Female
- Helicobacter Infections
(complications, drug therapy)
- Helicobacter pylori
(drug effects)
- Humans
- Male
- Omeprazole
(analogs & derivatives, therapeutic use)
- Rabeprazole
|